Carboplatin + Paclitaxel (Adjuvant/Palliative Chemotherapy)
Treatment for Uterine Cancer
Typical Dosage: Carboplatin AUC 5-6, Paclitaxel 175 mg/m2 IV every 3 weeks
Effectiveness
55%
Safety Score
25%
Clinical Trials
200
Participants
30K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Carboplatin AUC 5-6, Paclitaxel 175 mg/m2 IV every 3 weeks
Time to Effect
2-4 cycles (6-12 weeks)
Treatment Duration
3-6 cycles (3-6 months)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
4(Treat 4 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$45,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
MODERATEICER
$140,000/QALY
QALYs Gained
1
Outcome-Based Costs
Cost per Responder
$90,000
Cost per Remission
$180,000
Carboplatin + Paclitaxel (Adjuvant/Palliative Chemotherapy) Outcomes
for Uterine Cancer
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov